Skip to main content


Showing posts from December, 2011

Almost 16,000 COVID-19 patients get hydroxychloroquine and here's what happened

In a new study from Brigham and Women’s hospital, nearly 16,000 patient outcomes were analyzed that were diagnosed with COVID-19 and received the drug hydroxychloroquine.
Instead of improving, patients were four times more likely to experience dangerous heart irregularity, compared to those not teated with the antimalarial drug.
Patients in the study that were given hydroxychloroquine were also more likely to die.
The study is recently published in the medical journal The Lancet  and is the most recent to address a hot topic about whether the medication, which is also prescribed to treat autoimmune disorders, should be  used to treat COVID-19.
Mandeep R. Mehra, a corresponding study author and executive director of the Brigham’s Center for Advanced Heart  Disease said the drug, or any regimen including a chloroquine,  did not help “no matter which way you examine the data.”
Patients from six continents included 
The researchers looked at data from 671 hospitals that included six continents …

Arizona University Scientists Develop Ebola Vaccine

Researchers from Arizona University have developed a vaccine against the deadly Ebola virus that works on mice.

The scientists have found a way to grow and purify the vaccine using the tobacco plant. According to the finding, reported in more detail today at EmaxHealth, the production of the vaccine is inexpensive and could be stored for extended periods without expiring.

The Ebola vaccine is different because it doesn't use a live virus, which means it doesn't require special storage for safety reasons.

The vaccine isn't used to prevent Ebola, but instead provokes the body's immune system to fight the infection.

The next step is to see if the Ebola vaccine works as well humans as it did in mice.